{"id":"https://openalex.org/W1976741702","doi":"https://doi.org/10.1089/108729002760070830","title":"Evidence for Sequence-Dependent and Reversible Nonspecific Effects of PS-Capped Antisense Treatment After Intracerebral Administration","display_name":"Evidence for Sequence-Dependent and Reversible Nonspecific Effects of PS-Capped Antisense Treatment After Intracerebral Administration","publication_year":2002,"publication_date":"2002-04-01","ids":{"openalex":"https://openalex.org/W1976741702","doi":"https://doi.org/10.1089/108729002760070830","mag":"1976741702","pmid":"https://pubmed.ncbi.nlm.nih.gov/12074369"},"language":"en","primary_location":{"id":"doi:10.1089/108729002760070830","doi":"https://doi.org/10.1089/108729002760070830","is_oa":false,"landing_page_url":"https://doi.org/10.1089/108729002760070830","pdf_url":null,"source":{"id":"https://openalex.org/S92216883","display_name":"Antisense and Nucleic Acid Drug Development","issn_l":"1087-2906","issn":["1087-2906","2168-6599"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antisense and Nucleic Acid Drug Development","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5017391121","display_name":"Sandra M. Boye","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Sandra M. Boye","raw_affiliation_strings":["Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada H3G 1Y6"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada H3G 1Y6","institution_ids":["https://openalex.org/I5023651"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065566445","display_name":"Amynah A. A. Pradhan","orcid":"https://orcid.org/0000-0001-9691-2976","observed_orcids":["https://orcid.org/0000-0001-9691-2976"]},"institutions":[{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Amynah A.A. Pradhan","raw_affiliation_strings":["Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada H3G 1Y6"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada H3G 1Y6","institution_ids":["https://openalex.org/I5023651"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Rebecca J. Grant","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Rebecca J. Grant","raw_affiliation_strings":["Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada H3G 1Y6"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada H3G 1Y6","institution_ids":["https://openalex.org/I5023651"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5070837221","display_name":"Paul B. S. Clarke","orcid":"https://orcid.org/0000-0003-2666-2072","observed_orcids":["https://orcid.org/0000-0003-2666-2072"]},"institutions":[{"id":"https://openalex.org/I5023651","display_name":"McGill University","ror":"https://ror.org/01pxwe438","country_code":"CA","type":"education","lineage":["https://openalex.org/I5023651"]}],"countries":["CA"],"is_corresponding":false,"raw_author_name":"Paul B. S. Clarke","raw_affiliation_strings":["Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada H3G 1Y6"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada H3G 1Y6","institution_ids":["https://openalex.org/I5023651"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I5023651"],"apc_list":null,"apc_paid":null,"fwci":0.1912,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":{"value":0.42026032,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"12","issue":"2","first_page":"95","last_page":"102"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.8101000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.8101000189781189,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10432","display_name":"DNA and Nucleic Acid Chemistry","score":0.11580000072717667,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11818","display_name":"Nicotinic Acetylcholine Receptors Study","score":0.030700000002980232,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antisense-oligodeoxynucleotides","display_name":"antisense oligodeoxynucleotides","score":0.9150000214576721},{"id":"https://openalex.org/keywords/ventral-tegmental-area","display_name":"ventral tegmental area","score":0.8769999742507935},{"id":"https://openalex.org/keywords/neurotoxicity","display_name":"neurotoxicity","score":0.8109999895095825},{"id":"https://openalex.org/keywords/dopaminergic-denervation","display_name":"dopaminergic denervation","score":0.8790000081062317},{"id":"https://openalex.org/keywords/neurodegeneration","display_name":"neurodegeneration","score":0.8629999756813049},{"id":"https://openalex.org/keywords/functional-compensation","display_name":"functional compensation","score":0.718999981880188},{"id":"https://openalex.org/keywords/intracerebral-infusion","display_name":"intracerebral infusion","score":0.6169999837875366},{"id":"https://openalex.org/keywords/osmotic-minipump","display_name":"osmotic minipump","score":0.7210000157356262}],"concepts":[{"id":"https://openalex.org/C2780948874","wikidata":"https://www.wikidata.org/wiki/Q640562","display_name":"Ventral tegmental area","level":4,"score":0.7434929609298706},{"id":"https://openalex.org/C2779491297","wikidata":"https://www.wikidata.org/wiki/Q3338704","display_name":"Neurotoxicity","level":3,"score":0.6221132278442383},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.5878077149391174},{"id":"https://openalex.org/C2779547902","wikidata":"https://www.wikidata.org/wiki/Q28086552","display_name":"Nicotine","level":2,"score":0.5870748162269592},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5640435814857483},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.5225193500518799},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4770188331604004},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.355862557888031},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31416624784469604},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.30955833196640015},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.30529147386550903},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.264437198638916},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.21620669960975647}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001483","descriptor_name":"Base Sequence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001921","descriptor_name":"Brain","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D001921","descriptor_name":"Brain","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009043","descriptor_name":"Motor Activity","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D009043","descriptor_name":"Motor Activity","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D009714","descriptor_name":"Nucleus Accumbens","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D009714","descriptor_name":"Nucleus Accumbens","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D011978","descriptor_name":"Receptors, Nicotinic","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011978","descriptor_name":"Receptors, Nicotinic","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D011978","descriptor_name":"Receptors, Nicotinic","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D011978","descriptor_name":"Receptors, Nicotinic","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D013873","descriptor_name":"Thionucleotides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013873","descriptor_name":"Thionucleotides","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D013873","descriptor_name":"Thionucleotides","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D017207","descriptor_name":"Rats, Sprague-Dawley","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017557","descriptor_name":"Ventral Tegmental Area","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D017557","descriptor_name":"Ventral Tegmental Area","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D020319","descriptor_name":"Oligodeoxyribonucleotides, Antisense","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D020319","descriptor_name":"Oligodeoxyribonucleotides, Antisense","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D020319","descriptor_name":"Oligodeoxyribonucleotides, Antisense","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D021122","descriptor_name":"Protein Subunits","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1089/108729002760070830","doi":"https://doi.org/10.1089/108729002760070830","is_oa":false,"landing_page_url":"https://doi.org/10.1089/108729002760070830","pdf_url":null,"source":{"id":"https://openalex.org/S92216883","display_name":"Antisense and Nucleic Acid Drug Development","issn_l":"1087-2906","issn":["1087-2906","2168-6599"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core"],"host_organization":"https://openalex.org/P4310320443","host_organization_name":"Mary Ann Liebert, Inc.","host_organization_lineage":["https://openalex.org/P4310320443","https://openalex.org/P4310320017"],"host_organization_lineage_names":["Mary Ann Liebert, Inc.","SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antisense and Nucleic Acid Drug Development","raw_type":"journal-article"},{"id":"pmid:12074369","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/12074369","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antisense & nucleic acid drug development","raw_type":"Journal Article"},{"id":"mag:2343074079","doi":null,"is_oa":false,"landing_page_url":"https://online.liebertpub.com/doi/pdf/10.1089/108729002760070830","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9391000270843506,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320324195","display_name":"Medical Research Council Canada","ror":"https://ror.org/01gavpb45"},{"id":"https://openalex.org/F4320327918","display_name":"H. Lundbeck A/S","ror":"https://ror.org/0564cd633"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":43,"referenced_works":["https://openalex.org/W1615624892","https://openalex.org/W1651595496","https://openalex.org/W1651896244","https://openalex.org/W1972571094","https://openalex.org/W1978177900","https://openalex.org/W1983065458","https://openalex.org/W1986445622","https://openalex.org/W1986550480","https://openalex.org/W1988234472","https://openalex.org/W1990989480","https://openalex.org/W1991630622","https://openalex.org/W1993742630","https://openalex.org/W2003873821","https://openalex.org/W2003974173","https://openalex.org/W2005432373","https://openalex.org/W2008579253","https://openalex.org/W2015290966","https://openalex.org/W2016885417","https://openalex.org/W2018539096","https://openalex.org/W2023509166","https://openalex.org/W2025997520","https://openalex.org/W2027274005","https://openalex.org/W2028479508","https://openalex.org/W2029291587","https://openalex.org/W2030237537","https://openalex.org/W2038260132","https://openalex.org/W2043863702","https://openalex.org/W2054161560","https://openalex.org/W2061387768","https://openalex.org/W2065176243","https://openalex.org/W2068269961","https://openalex.org/W2081950565","https://openalex.org/W2083076890","https://openalex.org/W2083893845","https://openalex.org/W2103196103","https://openalex.org/W2158717355","https://openalex.org/W2163815564","https://openalex.org/W2165590312","https://openalex.org/W2167206808","https://openalex.org/W2184197616","https://openalex.org/W2226370386","https://openalex.org/W2268369589","https://openalex.org/W4320577279"],"related_works":["https://openalex.org/W2343074079","https://openalex.org/W2003974173","https://openalex.org/W2030237537","https://openalex.org/W2017414308","https://openalex.org/W2038260132","https://openalex.org/W4407669972","https://openalex.org/W6986625856","https://openalex.org/W2072007646","https://openalex.org/W4403809419","https://openalex.org/W2008658633"],"abstract_inverted_index":{"Phosphorothioate":[0],"(PS)-capped":[1],"phosphodiester":[2],"(PE)":[3],"oligodeoxynucleotides":[4],"(ODNs)":[5],"were":[6,54],"used":[7],"to":[8,44],"determine":[9],"whether":[10],"the":[11,94,137],"dopamine-dependent":[12],"locomotor-stimulant":[13],"effect":[14],"of":[15,34,131,139],"nicotine":[16,45],"is":[17],"mediated":[18],"via":[19,37],"a4":[20,35],"subunit-containing":[21],"nicotinic":[22],"receptors.":[23],"To":[24],"this":[25],"end,":[26],"rats":[27],"received":[28],"direct":[29],"intraventral":[30],"tegmental":[31,96],"area":[32],"infusion":[33,117],"antisense":[36,52,83,132],"osmotic":[38],"minipump,":[39],"and":[40,66,75,100,124,142],"their":[41],"locomotor":[42],"response":[43],"(0.2":[46],"mg/kg,":[47],"s.c.)":[48],"was":[49,64,73,79],"tested.":[50],"Eight":[51],"ODNs":[53],"screened,":[55],"but":[56],"only":[57],"one":[58],"inhibited":[59],"nicotine-induced":[60],"locomotion.":[61],"This":[62],"inhibition":[63],"reversible":[65],"selective,":[67],"insofar":[68],"as":[69],"basal":[70],"(saline)":[71],"activity":[72],"unaffected,":[74],"a":[76],"mismatch":[77],"ODN":[78],"without":[80],"effect.":[81],"However,":[82],"treatment":[84],"also":[85],"caused":[86],"sequence-dependent":[87],"toxic":[88,140],"effects,":[89],"including":[90],"neuronal":[91],"degeneration":[92],"in":[93],"ventral":[95],"area,":[97],"dopaminergic":[98],"denervation,":[99],"weight":[101],"loss.":[102],"We":[103],"conclude":[104],"that":[105],"despite":[106],"previous":[107],"reports,":[108],"PS-capped":[109],"PE-ODNs":[110],"can":[111],"cause":[112],"severe":[113],"neurotoxicity":[114],"on":[115],"chronic":[116],"into":[118],"brain":[119],"tissue.":[120],"Moreover,":[121],"sequence":[122],"dependence":[123],"temporal":[125],"reversibility,":[126],"two":[127],"generally":[128],"accepted":[129],"criteria":[130],"action,":[133],"may":[134],"sometimes":[135],"reflect":[136],"occurrence":[138],"effects":[141],"resultant":[143],"functional":[144],"compensation.":[145]},"counts_by_year":[{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}